Unique ID issued by UMIN | UMIN000005752 |
---|---|
Receipt number | R000006749 |
Scientific Title | Molecular hydrogen for ischemic stroke |
Date of disclosure of the study information | 2011/06/02 |
Last modified on | 2011/06/02 16:37:03 |
Molecular hydrogen for ischemic stroke
Hydrogen for cerebral ischemia
Molecular hydrogen for ischemic stroke
Hydrogen for cerebral ischemia
Japan |
Cerebral infarction
Cardiology | Neurology | Geriatrics |
Neurosurgery |
Others
NO
To investigate the safety and efficacy of molecular hydrogen for ischemic stroke
Safety,Efficacy
Confirmatory
Pragmatic
modified Rankin scale (mRS) (days 7, 30, and 90), the NIHSS (days 7 and 90), and the Barthel Index (days 7, 30, and 90)
Safety Assessments
Vital signs were recorded at enrollment and at specified times throughout the infusion and follow-up periods. Routine laboratory data and ECGs were performed at the time of enrollment, at 24 and 72 hours, and on day 7 and were analyzed centrally (ECGs at day 7 were performed only if abnormal at 72 hours). To assess any effect of hydrogen on hemorrhagic transformation after alteplase administration, brain imaging was repeated after 72 hours in patients who were receiving concomitant treatment with alteplase. Symptomatic hemorrhagic transformation was defined as an increase in the NIHSS score of at least 4 points within 36 hours, plus evidence of any blood on neuroimaging after treatment with alteplase. Patients meeting criteria for progressive stroke (NIHSS increase of 4 points within 72 hours) or new stroke in the first week were also reimaged.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
Intravenous drip infusion of hydrogen-rich saline
18 | years-old | <= |
120 | years-old | >= |
Male and Female
Patients were eligible for enrollment if they were 18 years or older and had a clinical diagnosis of acute ischemic stroke within 24 hours of symptom onset. They had to score at least 6 on the National Institutes of Health Stroke Scale (NIHSS) with at least 2 points for limb weakness. All patients received appropriate routine stroke care as per local treatment practices, including alteplase for eligible patients presenting 3 hours from onset; patients receiving alteplase had to commence the study drug before the alteplase infusion.
Patients with acute ischemic stroke beyond 24 hours of symptom onset.
20
1st name | |
Middle name | |
Last name | Hiroshi Nawashiro, M.D.,D.M.Sc. |
National Defense Medical College (NDMC)
Department of Neurosurgery
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
1st name | |
Middle name | |
Last name | Hiroshi Nawashiro, M.D.,D.M.Sc. |
National Defense Medical College (NDMC)
Department of Neurosurgery
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
04-2995-1656
nawa1957@ndmc.ac.jp
Department of Neurosurgery, National Defense Medical College
None
Ken-o-Tokorozawa Hospital
Tokorozawa Central Hospital
Self-Defense Forces Central Hospital
Kuki General Hospital
Nishijima Hospital
MiZ Co., Ltd.
CEO Fumitake Satoh
16-5, Zengyo 1-chome, Fujisawa-shi, Kanagawa-ken,
251-0871
Japan
NO
防衛医科大学校病院(埼玉県)National Defense Medical College Hospital (Saitama)
2011 | Year | 06 | Month | 02 | Day |
Unpublished
Open public recruiting
2011 | Year | 04 | Month | 01 | Day |
2011 | Year | 06 | Month | 01 | Day |
2013 | Year | 06 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2011 | Year | 06 | Month | 10 | Day |
2011 | Year | 06 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006749